85% of Clinical Drug Trials Face Delays. What’s the True Cost?
Clinical trials can save lives and provide new ways to treat disease. The industry estimates that 85% of all clinical trials face delays due to patient enrollment. Understanding that challenge and finding ways to minimize it is the pursuit of Jeeva Informatics. The company’s founder and CEO, Dr. Harsha Rajasimha, joined Kevin Stevenson on I Don’t Care to discuss the issue.
Dr. Rajasimha has a long history of clinical research experience, working as a data scientist and software engineer. After several personal tragedies, he wanted to apply his knowledge to helping clinical research trials overcome logistical burdens to bring new treatments to market faster.
“The biggest barrier in clinical trials is delays in the timeline associated with patient recruitment. Traditionally, those enrollees must be within 50 miles of the lab,” Dr. Rajasimha explained. That narrows down access considerably. “Only 1.2% of cancer patients in the U.S. are in a clinical trial.”
The other challenge is the logistics. Patients must travel to sites for treatment or simply just exchanges with physicians. “It’s a travel burden for patients and their caregivers,” Dr. Rajasimha noted.
To change the clinical trial ecosystem, Dr. Rajasimha said that the paradigm of the four walls of the lab must evolve. “Clinical trials have been slow to adopt digital channels, but the pandemic forced this.”
By digitizing and automating repetitive manual tasks, the burden of participation shrinks for the patient. “The pandemic showed that there is a demand for flexibility in decentralizing clinical trials. With the right tools, this is possible,” Dr. Rajasimha explained.
By leveraging technology, clinical trial producers can maximize diversity, equity, and inclusion. With more communication and interaction, patients in trials are also more likely to adhere to medication instructions and be more trusting of the process
More Like This Story:
Is the FDA’s Accelerated Approval of Molnupiravir Setting a Pharmaceutical Standard?
From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs
Latest
Mark Tina Envisions Differences to the Verizon Partner Network in 2024
In the dynamic telecommunications landscape, Verizon’s Partner Network continues to evolve, adapting to new trends and opportunities. For another segment featuring Mark Tina, VP of Indirect Channel Distribution and Channel Chief at Verizon Business Group, he explores exactly what types of significant changes and advancements the Verizon Partner Network will see in 2024. In this […]
Mark Tina Explores the Importance of Partners in Verizon Business Group Success
A special episode of The Verizon Partner Network focuses on an examination of an industry marked by fierce competition and rapid innovation. But most importantly, how the role of partnerships in a company’s success is increasingly vital. Mark Tina, the VP of Indirect Channel Distribution and Channel Chief at Verizon, details why partners are essential […]
Mark Tina Highlights Three Pillars of Success in Verizon’s Partner Network
For a continuation episode of The Verizon Partner Network’s special segment with team leaders, Mark Tina, VP of Indirect Channel Distribution and Channel Chief at Verizon Business Group, joined again to outline the three top aspects that define the Verizon Partner Network and its approach to collaborative success. The video centers on Tina’s explanation of […]
